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Accurate blood group antigen typing of red blood cells with a posi-
tive direct antiglobulin test or from a recently transfused patient has
been a long-standing problem.  To overcome this problem, we eval-
uated the feasibility of using somatic cells as a source of DNA for
molecular genotyping.  Two sources of cells that could be obtained
by noninvasive procedures were chosen for analysis: urine samples,
which were already available in the clinical laboratory, and buccal
epithelial cells collected with cotton wool swabs.  DNA, prepared
using a commercial kit, was subjected to polymerase chain reaction
amplification and followed by digestion with the appropriate restric-
tion enzyme.  Genotyping was performed for three alleles encoded
by polymorphic genes on three different chromosomes, namely
KEL1/KEL2, JKA/JKB, and FYA/FYB.  Genotyping results were com-
pared to the results of typing performed on red blood cells using
standard hemagglutination techniques.  Results given by samples
freshly collected from volunteer donors were concordant. Although
results obtained with samples collected from hospital patients were
initially not in agreement with the phenotyping results, adjustments
to the test protocol resulted in concordance.  DNA from blood, urine
sediment, or buccal cells can be used for blood group molecular
genotyping.  Immunohematology 15;2:61–65.
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Accurate phenotyping of red blood cells (RBCs) from
recently transfused patients is problematic because of
the presence of transfused donor(s) RBCs in the circula-
tion of the recipient. This problem is particularly true for
patients who have been recently transfused with multi-
ple units of RBCs. Accurate phenotyping of antigens
using reagents that only react by the antiglobulin test is
also problematic when the patient’s RBCs have a posi-
tive direct antiglobulin test (DAT). In these situations, it
would be valuable to have an alternative to hemaggluti-
nation tests to determine the patient’s antigen profile as
part of an antibody identification process.
In recent years, technological advances have led to
the understanding of the molecular basis of many blood
group antigens. The majority of blood group polymor-
phisms are associated with a single-point mutation in the
gene encoding the protein carrying the blood group
antigen.1-3 Thus, blood typing at the molecular level
using DNA can be used to circumvent the phenotyping
difficulties mentioned above. If DNA is prepared from a
transfused patient’s blood sample, donor leukocytes
could, at least theoretically, interfere with genotyping
results.4-7 To avoid this potential problem, we evaluated
the feasibility of using sources of DNA other than RBCs
to determine the blood group genotype. Because the
genetic code is contained within all somatic cells, it is
theoretically possible for molecular determination of
blood group antigens in multitransfused patients to be
performed on alternative sources of DNA, thereby avoid-
ing the difficulties caused by transfused RBCs in cur-
rently used RBC phenotyping methods. We collected
two sources of cells using noninvasive procedures,
namely urine samples that were already available in the
clinical laboratory, and buccal epithelial cells collected
with cotton wool swabs. To test our approach, we per-
formed genotyping for three pairs of alleles encoded by
polymorphic genes on three different chromosomes,
namely, KEL1/KEL2, JKA/JKB, and FYA/FYB. In the
Duffy genotype, it has been reported that a mutation in
the erythroid promoter motif (GATA-1 box) silences the
FYB gene expression.8 Therefore, we also performed
restriction fragment length polymorphism (RFLP) analy-
sis for this point mutation and confirmed that it is criti-
cal to analyze the associated GATA-1 box for accurate
correlation between Duffy genotype and phenotype.
Material and Methods
Sample collection
Institutional Review Board approval in the authors’
institutions was obtained prior to the collection of sam-
ples. Blood samples were obtained from patients or
donors whose RBC phenotype had been determined on
the current or previous sample. Urine samples were
either surplus to the needs of the clinical chemistry lab-
oratory or collected specifically. We obtained buccal
epithelial cells by swiping the mouth mucosa with a cot-
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ton wool swab. The swab was placed in a tube and stop-
pered for transport. Whenever possible, blood samples,
urine samples, and buccal smears were obtained from
each person. RBC antigen typing was performed by
standard hemagglutination tube tests using antisera from
several commercial sources. The genotyping tests were
performed and interpreted without knowledge of the
phenotyping results. The results obtained on DNA from
different cell sources were compared to each other, fol-
lowed by comparison with the K/k, Jka/Jkb, and Fya/Fyb
antigen typing.
DNA extraction
DNA was extracted from whole blood samples using
the Easy DNA Kit (Invitrogen, Carlsbad, CA), protocol 2
(page 6 in the instruction manual). Urine samples were
centrifuged to pellet nucleated cells (presumed to origi-
nate from urinary tract epithelia and/or white blood
cells), and DNA was extracted from this pellet using the
Easy DNA Kit protocol 3 (page 7 in the instruction man-
ual). Buccal cells trapped in the external layer of the cot-
ton swab were placed into a tube containing 200 μL of
sterile phosphate-buffered saline, and DNA was extract-
ed using the Easy DNA Kit protocol 3. Extracted DNA
was analyzed for quality (degradation/integrity) by
examining the pattern obtained after agarose gel electro-
phoresis, and the quantity was estimated by spectropho-
tometrical reading of the optical density at 260 nm.
Amplification conditions and profile
Polymerase chain reactions (PCR) were performed
with approximately 200 ng of DNA using specific
primers flanking the polymorphism for each blood
group allele. Primers with high melting temperatures
were preferentially chosen in order to allow high strin-
gency. Concentrations of primers and magnesium chlo-
ride were adjusted so that the same PCR profile could be
used for each allele. The amplification profile was 94°C
for 5 minutes followed by 35 cycles of amplification con-
sisting of denaturation at 94°C for 20 seconds, annealing
at 62°C for 15 seconds, and elongation at 72°C for 20
seconds. This was followed by 10 minutes at 72°C. PCR
buffers and Taq DNA polymerase were purchased from
Promega (Madison, WI) or Perkin-Elmer (Branchburg,
NJ). Amplified products were subjected to elec-
trophoresis in 1.2% agarose gel in tris-acetate-EDTA
(TAE) to verify amplification efficiency before restriction
enzyme treatment for genotype determination. The
primer sequences8-12 and amplicon sizes are given in
Table 1.
Table 1. Sequence of primers and PCR product size
Amplicon 
Allele Primer sequence size
KEL1/KEL2 KEL-S 5'-AAG CTT GGA GGC TGG CGC AT –3' 156 bp
KEL-R 5'-CCT CAC CTG GAT GAC TGG TG –3'
JKA/JKB JKIS 5'-TGA GAT CTT GGC TTC CTA GG –3' * 210 bp
JK2 5'- ATT GCA ATG CAG GCC AGA GA 3'
FYA/FYB FYAB1 5'- TCC CCC TCA ACT GAG AAC TC –3' 392 bp
FYAB2 5'- AAG GCT GAG CCA TAC CAG AC –3'
GATA FYN1 5'– CAA GGC CAG TGA CCC CCA TA –3' 189 bp
FYN2 5'– CAT GGC ACC GTT TGG TTC TC –3'
*Primer based on intronic sequence determined in the authors’ laboratory
PCR product analysis for genotype determination
The PCR-amplified products were analyzed by appro-
priate restriction enzymes to identify specific point
mutations. Enzymes were purchased from New England
Biolab (Beverly, MA) and used according to manufactur-
er’s instructions. The enzymes Bsm I, Mnl I, and Ban I
were used to determine, respectively, KEL1/KEL2
(C698T), JKA/JKB (A838G), and FYA/FYB (A306G).9-12
Furthermore, the Sty I enzyme was used to distinguish
between functional and nonfunctional GATA-1 box (T-
46C)—a functional GATA-1 box being critical for expres-
sion of Fyb protein in the red cell membrane.8,13,14 All
digestion incubations were performed overnight. After
digestion, RFLPs were analyzed by electrophoresis in 3%
agarose in TAE stained with ethidium bromide and com-
pared with molecular standards. For the GATA box anal-
ysis, electrophoresis in 8% acrylamide gel in tris-borate-
EDTA with ethidium bromide was required.
Results
Tests on samples from volunteer donors
Blood,urine,and buccal swab samples were collected
from 16 healthy volunteers. The molecular genotyping
results on DNA prepared from blood, urine, and buccal
cells for Kell and Kidd alleles were concordant with the
hemagglutination results. Two samples that genotyped
as KEL1/KEL2 had been typed as K+k+, and 14 samples
that genotyped as KEL2/KEL2 had been typed as K–k+.
Six samples that genotyped as JKA/JKA had been typed
as Jk(a+b–), seven samples that genotyped as JKA/JKB
had been typed as Jk(a+b+), and three samples that
typed as Jk(a–b+) were genotyped as JKB/JKB.
Molecular genotyping results for Duffy were concor-
dant with the hemagglutination typing in the 12 samples
that had a double dose of the functional erythroid GATA-
1 box (GATA+/+; see Table 2). The other four samples
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typed as Fy(a–b–), genotyped as FYB/FYB, and had a
mutation in the GATA-1 box (GATA–/–). This apparent
pseudo-disagreement of results is consistent with previ-
ously reported observations8 that the FYB gene can be
silenced by a mutation in the GATA-1 box.
Table 2. Results of Duffy testing on 16 volunteer donors
RBC Phenotypes
Genotype Fy(a+b–) Fy(a+b+) Fy(a–b+) Fy(a–b–)
FYA/FYA 3 0 0 0
GATA (+/+)
FYA/FYB 0 6 0 0
GATA (+/+)
FYB/FYB 0 0 3 0
GATA (+/+)
FYB/FYB 0 0 0 4
GATA (–/–)
Tests on samples from patients
In order to evaluate collection and performance in
the actual clinical setting,we collected urine and/or buc-
cal swab samples from 20 patients whose RBCs had
been phenotyped previously. For a variety of reasons,we
were unable to collect both urine and buccal smear sam-
ples from all 20 patients. Initially, when genotyping
results were compared with phenotyping results, sever-
al discrepant results were noted. For this reason, the fol-
lowing adjustments were made to our testing protocol
as given in Materials and Methods. We used hot-start
PCR combined with high stringency annealing tempera-
tures in order to decrease primer-dimer formation, we
designed primers flanking shorter genomic sequences
to facilitate amplification of small quantities or of poor-
quality DNA, and we replaced 4% agarose gels with 8%
polycrylamide gel electrophoresis to resolve small dif-
ferences in the sizes of the digestion products. Once
these adjustments had been made, genotyping was
repeated in a blinded fashion. In all cases, the genotyp-
ing results obtained on analysis of DNA from the differ-
ent sources were in agreement.
The molecular genotyping on DNA prepared from
urine and/or buccal cells was concordant with the
hemagglutination results on record for Kell and Kidd
alleles. All 20 samples were genotyped as KEL2/KEL2
and had K–k+ RBCs. Seven samples that were geno-
typed as JKA/JKA had been typed as Jk(a+b–),nine sam-
ples that were genotyped as JKA/JKB had been typed as
Jk(a+b+), and four samples that genotyped as JKB/JKB
had been typed as Jk(a–b+).
Molecular genotyping results for Duffy were concor-
dant with hemagglutination typing in 13 samples that
had a double dose of the functional erythroid GATA-1
box (Table 3). One sample (CB) with Fy(a–b–) RBCs had
the FYB/FYB genotype with one copy of the functional
and one copy of the nonfunctional GATA-1 box. This
sample was shown also to have heterozygous mutations
at nucleotides 271 and 304, which also silence the FYB
allele.15 Another sample (BR) had the FYA/FYB geno-
type with one copy of the functional GATA-1 box and
one copy of the nonfunctional GATA-1 box but Fy(a–b–)
RBCs; unfortunately, insufficient DNA was available for
further study and it was not possible to obtain a fresh
sample. Thus, we could not investigate the cause of the
silencing of the FYA allele; we presume that the non-
functional GATA-1 box silenced the FYB allele in BR.
The three other Fy(a–b–) samples were from African
American patients and had the expected homozygous
mutation in the GATA-1 box. One Fy(a+b–) patient (YM)
had the FYA/FYB genotype and was heterozygous for a
GATA-1 mutation that silenced the FYB allele. One
Fy(a–b+) patient (CQ) had a FYB/FYB genotype and
was also heterozygous for the GATA-1 mutation that
silenced one FYB allele.
Table 3. Results of Duffy testing on 20 patient samples
RBC Phenotypes
Genotype Fy(a+b–) Fy(a+b+) Fy(a-b+) Fy(a–b–)
FYA/FYA
GATA (+/+) 1 0 0 0
FYA/FYA
GATA (+/–) 0 0 0 0
FYA/FYB
GATA (+/+) 0 5 0 0
FYA/FYB
GATA (+/–) 1 (YM) 0 0 1 (BR)
FYB/FYB
GATA (+/+) 0 0 7 0
FYB/FYB
GATA (+/–) 0 0 1 (CQ) 1 (CB)
FYB/FYB
GATA (–/–) 0 0 0 3
Discussion
Our results show that DNA from leukocytes, urine
sediment, and buccal epithelial cells can be used for
blood group genotyping. This is of particular value in
genotyping patients who have been recently transfused
(when donor white blood cells may be circulating)4,5 or
whose RBCs are positive in the DAT. The ability to use
DNA from somatic cells also may be useful during preg-
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nancy when the maternal peripheral blood may contain
nucleated cells from the fetus.16 However,because 11 of
the patient samples were collected from women on
their first or second day postpartum, when fetal cells
would be expected to be present in the circulation, our
data show that the PCR-RFLP protocols that we used did
not detect interference by fetal cells. Our data also con-
firm that analysis of the GATA box is critical for accurate
correlation between Duffy genotyping and phenotyp-
ing.4,13,14
Although phenotyping of DNA from somatic cells can
be performed for any blood group for which the molec-
ular basis is known, this approach has limitations. One
unforeseen limitation was the effect of small quantities
or poor quality of DNA from specimens collected in an
in-patient setting compared with volunteer donors. The
former may require adjustments in PCR technique or in
sample preparations. In addition, it is possible that,
whereas analysis of genomic DNA indicates the pres-
ence of an apparently normal gene, the RNA may not be
transcribed or correctly spliced. Furthermore, the
encoded product may not be expressed in the RBC
membrane. Although these events are considered to be
rare in the general population, even our small sample of
20 patients revealed variant forms of the FY gene in
Hispanics as well as in African Americans. Nevertheless,
pseudo-disagreement of genotype and phenotype would
apply regardless of the source of DNA used for the
molecular genotyping, and we have clearly shown that
molecular genotyping for blood groups can be per-
formed on DNA prepared from white blood cells, urine
sediment, or buccal epithelial cells.
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